Apollomics, a novel US-China oncology company, was approved to start China Phase I trial of an E-selectin inhibitor in patients with acute myeloid leukemia. China 's NMPA has also accepted a Phase III bridging study of APL-106 (uproleselan) in combination with chemotherapy. Earlier this year, Apollomics acquired China rights to the candidate from GlycoMimetics of the US , which is conducting a Phase III trial of APL-106. Previously, Apollomics was known as CBT, the drug development spin-out of China-based cancer CRO Crown Biosciences. More details.... Stock Symbol: (NSDQ: GLYC) Share this with colleagues: // //